摘要
目的评价阿替普酶治疗急性脑梗死的疗效和安全性。方法 2011年1月-2012年3月收治的急性脑梗死患者共36例,给予阿替普酶溶栓治疗。结果溶栓后6 h,患者NIHSS较溶栓前明显降低(16.75±4.56 vs.23.89±6.17,P<0.05),24 h NIHSS较溶栓后6 h明显降低(10.78±3.72 vs.16.75±4.56,P<0.05),7d NIHSS较24 h明显降低(5.47±1.96 vs.10.78±3.72,P<0.05)。结论在一定的时间窗内,阿替普酶治疗急性脑梗死安全有效。
Objective To study the effect and safety of alteplase on acute cerebral infarction.Methods 36 patients with acute cerebral infarction were treated with alteplase from January 2011 to March 2012.Results After 6 h of thrombolytic therapy,the NIHSS decreased obviously（16.75±4.56 vs.23.89±6.17,P0.05）,and there was significant difference in NIHSS between the 6th and 24th hour（10.78±3.72 vs.16.75±4.56,P0.05）as well as 24th hour and 7th day（5.47±1.96 vs.10.78±3.72,P0.05）.Conclusion Intravenous thrombolytic therapy of alteplase is a safe and effective treatment for acute cerebral infarction within a certain therapeutic time window.
出处
《实用药物与临床》
CAS
2012年第10期635-636,共2页
Practical Pharmacy and Clinical Remedies
关键词
急性脑梗死
阿替普酶
静脉溶栓
Acute cerebral infarction
Alteplase
Intravenous thrombolysis
